Navigation Links
Remedium Technologies Inc. Awarded $500,000 Phase II NSF SBIR Grant to Test Sprayable Foam for Stopping Traumatic Bleeding
Date:4/16/2013

COLLEGE PARK, Md., April 16, 2013 /PRNewswire-USNewswire/ -- Remedium Technologies Inc., a medical device company developing innovative products to control severe hemorrhaging, was awarded a $500,000 Small Business Innovation Research (SBIR) grant from the National Science Foundation to test the company's sprayable foam for rapidly halting traumatic bleeding, company officials announce today.

In collaboration with Massachusetts General Hospital and the University of Maryland, Remedium will complete pre-clinical trials to evaluate the safety and efficacy of Hemogrip™ Foam in controlling non-compressible hemorrhaging, i.e., bleeding not accessible to direct pressure.  Hemogrip™ is a high-pressure, sprayable foam that can expand into an injured body cavity, adhere to tissue and stop hemorrhaging within minutes during the expansion process. There are currently no hemostatic products available for treatment of non-compressible bleeds, which account for 85 percent of hemorrhage-related deaths.

"Remedium is honored to be recognized for its product development progress with this important Phase II funding from the National Science Foundation," said Matthew Dowling , CEO and co-founder of Remedium. "We are enthusiastic in approaching pre-clinical trials with a product we see as critical in addressing non-compressible hemorrhage, which is one of the biggest unmet needs in trauma medicine today."

Hemogrip's™ life-saving technology is based on chitosan—a natural biopolymer found in the exoskeleton of shrimp, crabs, and other crustaceans. Chitosan is unique as a natural material because it is biocompatible, anti-microbial, and highly durable under a wide range of environmental conditions. When applied to wounds, Hemogrip™ creates a nano-scale, three-dimensional mesh, rapidly coagulating blood and staunching blood loss.

The Hemogrip™ Foam is dispensed from a handheld, lightweight canister that is easy to use by surgeons, soldiers and consumers alike. It can be removed quickly and easily without damaging tissue, and since it is based on chitosan—the second most abundant biopolymer on earth—it is also inexpensive.

Remedium was previously awarded a $150,000 SBIR Phase I grant from NSF to demonstrate the biological proof-of-concept of the sprayable foam. The company was also recently awarded a $200,000 Translational Research Award from the Maryland Biotechnology Center.

The company has six patents pending related to the Hemogrip™ platform.

About Remedium Technologies Inc.
Remedium Technologies is a medical device start-up that operates with a vision of user-directed advancement in the standard of care for the control of severe hemorrhage. The principals of Remedium Technologies have created a proprietary life-saving technology called Hemogrip™ which acts to stop traumatic bleeding rapidly. As the active component in a suite of pipeline products under development, Hemogrip™ is a uniquely user-friendly hemostat which is able to orchestrate the self-assembly of a clot-like seal upon contact with blood. It can be used effectively by a surgeon, by a soldier, or by an unskilled "buddy." Working under grants from the National Science Foundation and the United States Army Research Lab, Remedium Technologies is dedicated to saving lives both in the field and in the operating room.


'/>"/>
SOURCE Remedium Technologies Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. What Will Thermo Fisher Scientific and Life Technologies $14 billion Merger hold for the Top Ten Suppliers of Synthetic Biology Technology and DNA Sequencing Landscape?
2. Multisorb Technologies Non-Toxic StabilOx Oxygen Absorbing Canisters Provide Worry-Free Drug Stability
3. Ajinomoto Co., Inc. Completes Acquisition of Althea Technologies, Inc.
4. Advances in Surgical Technologies Boost Demand for Efficient Bone Graft Substitutes, Finds Frost & Sullivan
5. Cantel Medicals Mar Cor Purification Subsidiary Acquires Hemodialysis Water Business from Siemens Water Technologies Business Unit
6. SafeCode Drug Technologies Initiating Activities to Commercialize its Recent Newly Acquired Technology of the Pain-Free Injection
7. Research and Markets Announces the Release of Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities
8. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
9. Patient Safety Technologies Reports Fourth Quarter And Fiscal 2012 Results
10. Medbox Acquires 50% of MedVend and its Patented Technologies
11. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... -- Less than a month ago, amateur hackers executed an ... hospital networks, in over 150 countries. The ... online extortion attempts ever recorded. With the increasing complexity ... that providers understand where the risks lie, and how ... many other very real cyber threats.  ...
(Date:6/7/2017)... GAITHERSBURG, Md. , June 7, 2017  Novavax, Inc., ... the second of two Phase 2 trials of its RSV ... women of child bearing age have been published in the ... this publication have been shared in prior scientific conferences). The ... trial in April 2014. Novavax is developing the RSV F ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... London UK (PRWEB) , ... June 27, 2017 , ... ... a clinical study is whether they can trust the sponsor to pay them correctly ... vital that sponsors and CROs establish payment strategies that encourage sites to work on ...
(Date:6/27/2017)... ... , ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation ... and Affordable Care Act (ACA), would result in 22 million Americans losing their health ... More than 20 million Americans have gained health insurance under the ACA, and from ...
(Date:6/27/2017)... ... 27, 2017 , ... A January 18th article on medGadget reports ... billion by the year 2024 according to a new report. The article also notes ... from titanium. Los Angeles area clinic Beverly Hills Periodontics & Dental Implant Center says ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
Breaking Medicine News(10 mins):